| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
179,400,000 |
| Market
Cap: |
119.48(M) |
| Last
Volume: |
2,045,732 |
Avg
Vol: |
2,200,034 |
| 52
Week Range: |
$0.4904 - $1.48 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Delivery |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Nektar Therapeutics is a research-based biopharmaceutical company. Co.'s research and development pipeline of investigational drugs includes potential therapies for cancer and autoimmune disease. Co.'s proprietary programs include: Immuno-oncology, which involves in developing medicines that target biological pathways which stimulate and sustain the body's immune response in order to fight cancer; and Pain, NKTR-181, a mu-opioid analgesic drug candidate patients with chronic low back pain. Co.'s NKTR-358 is an investigational drug designed to correct the underlying immune system imbalance in the body which occurs in patients with autoimmune disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
43,916 |
89,030 |
380,005 |
604,765 |
| Total Sell Value |
$29,423 |
$74,988 |
$365,330 |
$619,047 |
| Total People Sold |
3 |
3 |
3 |
7 |
| Total Sell Transactions |
3 |
6 |
17 |
33 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Wilson Mark Andrew |
Chief Legal Officer |
• – – |
2025-05-19 |
4 |
S |
$0.67 |
$6,697 |
D/D |
(9,996) |
314,296 |
|
4% |
|
| Zalevsky Jonathan |
Chief R&D Officer |
• – – |
2025-05-19 |
4 |
S |
$0.67 |
$7,177 |
D/D |
(10,712) |
305,892 |
|
4% |
|
| Robin Howard W |
President & CEO |
• • – |
2025-05-19 |
4 |
S |
$0.67 |
$15,549 |
D/D |
(23,208) |
1,063,693 |
|
4% |
|
| Zalevsky Jonathan |
Chief R&D Officer |
• – – |
2025-02-19 |
4 |
S |
$1.01 |
$10,403 |
D/D |
(10,300) |
316,604 |
|
33% |
|
| Wilson Mark Andrew |
Chief Legal Officer |
• – – |
2025-02-19 |
4 |
S |
$1.01 |
$11,150 |
D/D |
(11,040) |
324,292 |
|
33% |
|
| Robin Howard W |
President & CEO |
• • – |
2025-02-19 |
4 |
S |
$1.01 |
$24,012 |
D/D |
(23,774) |
1,086,901 |
|
33% |
|
| Wilson Mark Andrew |
Chief Legal Officer |
• – – |
2024-12-24 |
4 |
S |
$0.89 |
$14,738 |
D/D |
(16,560) |
335,332 |
|
33% |
|
| Wilson Mark Andrew |
Chief Legal Officer |
• – – |
2024-12-23 |
4 |
S |
$0.90 |
$30,062 |
D/D |
(33,402) |
351,892 |
|
29% |
|
| Zalevsky Jonathan |
Chief R&D Officer |
• – – |
2024-12-19 |
4 |
S |
$0.94 |
$48,048 |
D/D |
(51,115) |
326,904 |
|
20% |
|
| Robin Howard W |
President & CEO |
• • – |
2024-12-18 |
4 |
S |
$0.99 |
$84,185 |
D/D |
(85,035) |
1,110,675 |
|
16% |
|
| Robin Howard W |
President & CEO |
• • – |
2024-12-17 |
4 |
S |
$1.01 |
$47,465 |
D/D |
(46,995) |
1,195,710 |
|
22% |
|
| Robin Howard W |
President & CEO |
• • – |
2024-12-13 |
4 |
A |
$0.00 |
$0 |
D/D |
410,625 |
1,242,705 |
|
- |
|
| Zalevsky Jonathan |
Chief R&D Officer |
• – – |
2024-12-13 |
4 |
A |
$0.00 |
$0 |
D/D |
135,000 |
378,019 |
|
- |
|
| Wilson Mark Andrew |
Chief Legal Officer |
• – – |
2024-12-13 |
4 |
A |
$0.00 |
$0 |
D/D |
165,938 |
385,294 |
|
- |
|
| Zalevsky Jonathan |
Chief R&D Officer |
• – – |
2024-11-19 |
4 |
S |
$1.01 |
$7,863 |
D/D |
(7,785) |
243,019 |
|
36% |
|
| Robin Howard W |
President & CEO |
• • – |
2024-11-19 |
4 |
S |
$1.01 |
$16,441 |
D/D |
(16,278) |
832,080 |
|
36% |
|
| Wilson Mark Andrew |
Chief Legal Officer |
• – – |
2024-11-19 |
4 |
S |
$1.01 |
$6,471 |
D/D |
(6,407) |
218,856 |
|
36% |
|
| Robin Howard W |
President & CEO |
• • – |
2024-08-19 |
4 |
S |
$1.28 |
$19,048 |
D/D |
(14,881) |
848,358 |
|
28% |
|
| Zalevsky Jonathan |
Chief R&D Officer |
• – – |
2024-08-19 |
4 |
S |
$1.28 |
$8,788 |
D/D |
(6,866) |
250,804 |
|
28% |
|
| Wilson Mark Andrew |
Chief Legal Officer |
• – – |
2024-08-19 |
4 |
S |
$1.28 |
$7,233 |
D/D |
(5,651) |
225,263 |
|
28% |
|
| Chess Robert |
|
– • – |
2024-06-14 |
4 |
AS |
$1.20 |
$23,400 |
D/D |
(19,500) |
255,273 |
|
15% |
|
| Zalevsky Jonathan |
Chief R&D Officer |
• – – |
2024-05-17 |
4 |
S |
$1.75 |
$12,871 |
D/D |
(7,355) |
257,670 |
|
33% |
|
| Wilson Mark Andrew |
Chief Legal Officer |
• – – |
2024-05-17 |
4 |
S |
$1.75 |
$10,955 |
D/D |
(6,260) |
230,414 |
|
33% |
|
| Robin Howard W |
President & CEO |
• • – |
2024-05-17 |
4 |
S |
$1.75 |
$29,138 |
D/D |
(16,650) |
863,239 |
|
33% |
|
| Kroin David |
|
– – • |
2024-05-10 |
4 |
S |
$1.78 |
$99,630 |
I/I |
(56,000) |
18,344,000 |
|
26% |
|
704 Records found
|
|
Page 1 of 29 |
|
|
